Hayanga J W Awori, Aboagye Jonathan K, Hayanga Heather K, Luketich James D, D'Cunha Jonathan
Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Heart Lung Transplant. 2016 Jul;35(7):901-5. doi: 10.1016/j.healun.2016.02.006. Epub 2016 Mar 10.
In this study we sought to determine survival rates after use of extracorporeal membrane oxygenation (ECMO) as a bridge to lung re-transplantation (re-LT).
Propensity-adjusted analysis was performed on data from the Scientific Registry of Transplant Recipients (SRTR) to evaluate survival in recipients between the years 1988 and 2012, based on the use of ECMO before re-LT.
A total of 854 adult re-LT recipients were identified. Extracorporeal support had been used as a bridge in 55 (6.8%) of the recipients, whereas 799 (93.2%) had undergone re-LT without the use of ECMO. Compared with non-ECMO patients, the ECMO patients were more likely to have: higher body mass index (p = 0.003); received lungs from an older donor (p = 0.04); higher total bilirubin (p = 0.002); undergone bilateral lung transplantation (p = 0.01); diabetes (p = 0.04); mechanical ventilation (p < 0.0005); and been hospitalized in the intensive care unit (p < 0.0001). They were also more likely to have a diagnosis of bronchiolitis obliterans syndrome (p < 0.0001), be on inhaled nitric oxide (p < 0.0001), and have a shorter waitlist time before re-LT (p < 0.0001). Compared with the non-ECMO group, 30-day survival for the ECMO group was lower (67.3% vs 91.2%, p = 0.0002). Obesity was identified as a predictor of increased mortality in re-LT hazard ratio 2.97 (1.18 to 7.50), p = 0.02.
This contemporary analysis of survival after use of ECMO as a bridge to re-LT revealed lower survival in the ECMO group.
在本研究中,我们试图确定使用体外膜肺氧合(ECMO)作为肺再次移植(re-LT)桥梁后的生存率。
对来自移植受者科学登记处(SRTR)的数据进行倾向调整分析,以评估1988年至2012年间接受再移植的受者的生存率,分析基于再移植前是否使用ECMO。
共确定了854名成年再移植受者。其中55名(6.8%)受者使用体外支持作为过渡,而799名(93.2%)受者在未使用ECMO的情况下接受了再移植。与未使用ECMO的患者相比,使用ECMO的患者更有可能:体重指数更高(p = 0.003);接受来自年龄较大供者的肺(p = 0.04);总胆红素水平更高(p = 0.002);接受双侧肺移植(p = 0.01);患有糖尿病(p = 0.04);接受机械通气(p < 0.0005);曾入住重症监护病房(p < 0.0001)。他们也更有可能被诊断为闭塞性细支气管炎综合征(p < 0.0001),使用吸入一氧化氮(p < 0.0001),并且在再次移植前等待名单时间更短(p < 0.0001)。与未使用ECMO组相比,使用ECMO组的30天生存率更低(67.3%对91.2%,p = 0.0002)。肥胖被确定为再移植死亡率增加的预测因素,风险比为2.97(1.18至7.50),p = 0.02。
这项关于使用ECMO作为再移植桥梁后生存率的当代分析显示,ECMO组的生存率较低。